All the available antiherpetic drugs are directed against viral proteins. Their extensive clinical use has led to the emergence of resistant viral strains. There is a need for the treatment of herpes infections due to resistant strains, especially for immunocompromised patients. To design new kinds of drugs, we have developed a strategy to identify cellular targets. Herpes simplex virus type 1 (HSV-1) infection is concomitant to a repression of most host protein synthesis. However, some cellular proteins continue to be efficiently synthesized. We speculated that some of them could determine the outcome of infection. Since two polyamines, spermidine and spermine, are components of the HSV-1 virions, we investigated whether enzymes involved in their synthesis could be required for viral infection. We show that inhibition of S-adenosyl methionine decarboxylase, a key enzyme of the polyamine metabolic pathway, prevents HSV-1 infection. Inhibition of polyamine synthesis prevents infection of culture cells with HSV-1 laboratory strains as well as clinical isolates that are resistant to the conventional antiviral drugs acyclovir and foscarnet. Our data provide the opportunity to develop molecules with a novel mechanism of action for the treatment of herpes infection.
infection allowing viral persistence. The latent virus can be periodically reactivated generally after fever, exposure to ultraviolet light (UV), menstrual cycle, and pregnancy. Over one-third of the world's population has recurrent HSV infections several times a year, with the capability of transmitting HSV by close personal contact (1) . Patients compromised by immunosuppressive therapy (drug treatment, solid organ, or bone marrow transplantation), or after infection by HIV, develop severe HSV infections with increased morbidity and mortality. Moreover, herpes infections are the most common causes of genital ulcers in industrialized countries. Genital herpes affects 20-90% of the world's adult population depending on the socio-cultural context, and today, an increasing number of genital herpes are caused by HSV-1 (2) . Neonatal herpes is one of the most serious complications of genital HSV infection. The newborn children who are infected at the time of birth have irreversible neurological damages in spite of anti-viral therapy (3).
For more than 15 years, acyclovir (ACV) and related drugs have been accepted as the treatment of choice for the management of HSV infections. ACV is a nucleoside analog that is specifically phosphorylated by viral thymidine kinase. The incorporation of the phosphorylated form of ACV within viral DNA prevents viral DNA replication. Consequently, ACV acts at the level of two viral enzymes, thymidine kinase and DNA polymerase. The widespread use of ACV and its derivatives has lead to the emergence of drug-resistant viruses, with spontaneous mutations in the DNA sequences coding for the viral thymidine kinase and DNA polymerase (4) . At present, all available anti-herpetic drugs act on viral enzymes and all the new potential anti-herpetic drugs are designed to target viral proteins, i.e., helicase or ribonucleotide reductase (5) . These considerations point out the crucial need for the development of new drugs that can inhibit replication of wild type as well as HSV viruses that are resistant to these more conventional drugs. An alternative to this traditional drug design approach is to target cellular proteins. Such novel antiviral drugs would be active against mutant viruses resistant to available drugs. The advantage of compounds that target cellular proteins is that, in theory, they would be active against a broad range of viruses. Today, the only demonstration that cellular proteins can be relevant targets for antiviral drugs is based on inhibition of cyclin-dependent kinases (6) .
For several years, we have used various proteomic approaches to unravel cellular proteins and metabolic pathways required for HSV-1 infection. HSV-1 gene expression is sequentially and temporally regulated through complex mechanisms. HSV-1 genes can be divided into immediate-early, early, and late genes according to their kinetics of expression (1) . HSV-1 protein synthesis is concomitant to a selective repression of host protein synthesis that is achieved both by mRNA degradation and by inhibition of translation of the remaining mRNA (7) (8) (9) . However, a small number of cellular proteins continue to be efficiently synthesized upon infection (8, 10-16). We have speculated that this particular class of cellular proteins could play a major role in determining the outcome of infection.
Spermidine (SPD) and spermine (SPM) are the final products of the polyamine biosynthetic pathway and are found in large amount in the mature virion. SPD is found in the envelope and SPM in the nucleocapsid (17). We have identified one of the cellular proteins that we have shown previously to escape the virally induced shutoff of cellular protein synthesis (14) as being ornithine decarboxylase (ODC) (unpublished results). ODC is one of the key enzymes of the polyamine biosynthetic pathway. Contradictory results are published on the relationship between the two key enzymes of polyamine synthesis, ODC and S-adenosyl methionine decarboxylase (SAMDC), and HSV-1 infection (18-20). Indeed, some authors demonstrated that inactivation of ODC or SAMDC has no effect on HSV replication, whereas others showed that HSV infection is prevented in cells where ODC activity is inhibited. In the present study, we provide new data allowing to a clear conclusion about the effect of inhibition of ODC and SAMDC activities on the infection of culture cells with wild-type HSV-1 viruses as well as HSV-1 mutant strains that are resistant to conventional treatments ACV and foscarnet.
MATERIALS AND METHODS

Cell lines and virus strain
Monolayer cells were grown in Eagle's minimum essential medium (E-MEM) containing 100 U/ml penicillin and 100 U/ml streptomycin and with or without 5% heat-inactivated fetal calf serum (FCS) at 37°C under 5% CO 2 . HSV-1 macroplaque strain (MP) was obtained from B. Jacquemont (Lyon, France) and was a gift of B. Roizman (Chicago, IL).
Infection of cells and MGBG treatment
HEp2 and HeLa cells were grown in 6-wells plates (~10 6 cells/well) and 150 mm diameter plates, respectively, and infected just before confluence with various multiplicity of infection (MOI) in E-MEM in absence of FCS, except when indicated. After 1 h adsorption of the virus at 33°C under 5% CO 2 , the medium was removed and the cells were washed and then incubated in E-MEM without FCS at 37°C until harvesting. Times postinfection were calculated from the time of addition of the virus.
Preparation of drugs
D,L-(difluoromethyl)ornithine (DFMO), methylglyoxal bis(guanylhydrazone) (MGBG), SPM, ACV, and foscarnet were purchased from Sigma. The stock solutions were diluted in water, and final dilutions of drugs in E-MEM were prepared immediately before use. Treatment and time of exposure of cells to the drugs are indicated in the figure legends. Medium was replaced every 24 h with fresh medium containing the same concentration of drug(s).
Plaque assays
HEp2 cells in six-well plates were inoculated with serial 10-fold dilutions of progeny virus. After a 1 h adsorption period at 33°C, the inoculum was removed and the cells were thoroughly washed with PBS and then overlaid with E-MEM. Plaques were counted and visualized at 72 h postinfection by fixing and staining the cells with 5% methylene blue in 70% methanol.
Measurement of the amount of mRNA and DNA
HEp2 cells pretreated or not with MGBG were infected in the presence or absence of MGBG. At the indicated times after infection, the medium was removed, and cells were washed with cold PBS and then scraped into PBS. Total RNA and DNA were purified using Qiagen RNA/DNA kit. RNA was submitted to DNase/RNase-free digestion (1.5 unit/µg), and DNA were submitted to RNase A digestion (10 units/µg). Quantitation of SAMDC mRNA and of viral mRNAs and DNA present in each sample was determined by slot blot analysis. For this, DNA in 100 µl buffer (10 mM Tris, 10 mM EDTA, 0.4 N NaOH) was denatured at 100°C for 10 min. Total RNA in 40 µl of formamide 50% (V/V), formaldehyde 7% (V/V), and 1× SSC were denatured at 70°C for 5 min. DNA and RNA samples were blotted under vacuum to a nylon positive membrane (Appligene) and then UV cross-linked and hybridized with the following [ 32 P]-labeled probes. The 1250 bp PstI/PvuII fragment of pSAMr1 plasmid (21) was used to detect SAMDC mRNA. The 746 bp SalI-EcoNI fragment of pSG28 and the 1308 bp MluI fragment of pSG124 plasmids (22) were used to detect the immediate-early ICP27 and the early UL42 viral mRNAs, respectively. The late Us11 mRNA was detected using the 230 bp XhoI fragment of pHSV-Us11 plasmid (23) . Viral DNA was detected using the ICP27 probe. Hybridized mRNA and DNA were revealed and quantified by scanning densitometry of the membranes with a PhosphorImager SI and the ImageQuant software (Amersham Pharmacia Biotech).
Distribution of mRNAs among polyribosomal fractions
Polyribosomes were prepared from 8 × 10 6 of mock-infected and HSV-1-infected HeLa cells (20 PFU per cell). Fractionation of polyribosomes on sucrose gradients was carried out from postmitochondrial supernatants (8). Briefly, cells were washed in cold PBS containing 100 µg/ml cycloheximide, scraped off, and collected in PBS. Postmitochondrial supernatants were obtained in Tris buffer containing 25 mM KCl and 100 µg/ml cycloheximide and layered onto 10-40% linear sucrose gradients containing 2 mM DTE. After centrifugation in SW41 rotor (Beckman) at 40,000 rpm for 105 min, 20 fractions of identical volume were collected from the gradient and treated for 15 min with 100 µg/ml proteinase K and 1% SDS before RNA extraction. Total RNA was resuspended in 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 1 U of RNase inhibitor (Amersham Pharmacia Biotech). The quantitative distribution of the various mRNAs among the 20 fractions was analyzed by slot blots as described above.
SPM quantitation
Cells grown in six-well plates were treated with 100 µM MGBG for 12 or 24 h. MGBG was added to infected cells (0.5 PFU per cell) concomitantly with the viral suspension. After centrifugation, cells were resuspended in HClO 4 0.4 N. Cell extracts and standards (SPM and diaminoheptane as an internal standard) were dansylated according to the procedure described by Seiler (24) and were then treated using the protocol adapted from Besson et al. (25) . The separation of polyamines and the quantification of SPM were performed by reverse phase high performance chromatography (26) . Peak areas were automatically measured by the integrator and evaluated according to the calibration method (27) . The absolute limit of detection per injection was 1 pmol for dansylated SPM. Mock-infected cells grown in the absence of MGBG were used as the control of intracellular SPM content and were therefore used as 100% value.
Estimation of cell viability
HEp2 cells were grown in a 3 cm diameter dish in the absence (control) and the presence of 10-500 µM of MGBG. At the time of harvesting, culture medium was collected from wells. Cells from the monolayers were trypsinized and added to the corresponding previous cell culture medium. Total cells were collected by centrifugation at 500 g and resuspended in PBS containing 0.2% trypan blue. Total, living, and dead cells were counted with a Malassez hematocytometer.
Detection of viral proteins
Mock-infected and infected HEp2 cells were washed three times with cold PBS, scrapped into PBS, and collected by centrifugation. Viral proteins (10 µg aliquots) were analyzed by Western blots using a 50× dilution of either a rabbit polyclonal anti-ICP27 antibody, or anti-Us11 antibody (28) , or a mouse monoclonal anti-UL42 antibody. Anti-ICP27 and anti-UL42 antibodies were kindly provided by Dr. Marsden (antibodies 42 and Z1F11, respectively) (29, 30) . Proteins were revealed by ECL (Amersham Biosciences) using an anti-rabbit or an antimouse peroxydase-conjugate (Sigma) diluted 1:10000. Cycloheximide was used at 1.5 µg/ml to completely inhibit viral replication, and a control of virus titer with no drug was included. After 24 h incubation at 37°C with 5% CO 2 , MGBG containing medium was replaced with freshly prepared dilutions of MGBG. Viral multiplication was monitored 24 h afterwards by an ELISA (35), using a rabbit monoclonal anti-HSV-1 antibody (BO 114, Dako) and a protein A peroxidase-conjugated (BioRad). The substrate, 2,2′-azino-di(3-ethyl-benzthiazoline) sulfonic acid (ABTS) diluted in ABTS buffer (Boehringer, Mannheim), was added to each well. After 30 min at room temperature, optical densities were read at 405 nm with a multichannel spectrophotometer (TitertekMultiskan). Optical density values were used with the Biolise program (Life Sciences International) to calculate the concentration of the drug causing a 50% inhibition of viral replication (IC 50 ) by logistic regression analysis (36) .
Antiviral susceptibility testing
RESULTS
Incidence of inhibition of SAMDC activity on HSV-1 infection
We investigated whether ODC and SAMDC activities are required for the outcome of infection. HEp2 cells were infected with HSV-1 in the presence of DFMO or MGBG in order to inhibit ODC and SAMDC, respectively. The MP viral strain exhibits the ability to induce the formation of large syncitia. Therefore, the effect of drugs on viral infection was first analyzed at the level of syncitia formation. These experiments were performed without SVF from the beginning of the treatment.
The number of syncitia was reduced only slightly in cells infected in the presence of DFMO compared with untreated cells, indicating that inhibition of ODC activity slightly prevents infection (Fig. 1A, a and b) . On the contrary, in cells infected in the presence of 10-100 µM of MGBG, the size and the number of syncitia were reduced compared with the control of infected cells not exposed to MGBG (Fig. 1A , a and c). Infection was almost totally inhibited in the presence of 100 µM MGBG, and the MGBG-induced inhibition of infection is MGBG dose dependent. In experiments performed with cells grown in the presence of 5% SVF, infection was still inhibited in a MGBG dose-dependant manner but less efficiently compared with cells grown in SVF-free medium (data not shown).
Effect of MGBG pretreatment on viral infection
We investigated whether treatment with MGBG before infection could influence the inhibition of infection. Cells grown in SVF-free medium were pre-exposed or not for 6 and 24 h to 10-300 µM MGBG, and then infected as described above, and the amounts of syncitia were estimated at 24 h postinfection (Fig. 1B) . Inhibition of infection was more complete in cells pre-exposed to MGBG than in cells not pre-exposed, even when the concentration of MGBG was low. For example, in the presence of 50 µM MGBG, there was 5× and 340× less syncitia formed, respectively, in cells not pre-exposed to MGBG and in cells pretreated for 24 h with MGBG compared with the control of untreated infected cells. In cells pre-exposed for 6 h and 24 h to 100-300 µM MGBG, infection was totally inhibited.
Effect of MGBG on the amount of infectious progeny virus
Because the syncitia formation test is an indirect evaluation of viral production, the influence of MGBG treatment was then determined directly by estimating the numbers of infectious progeny viruses. For this, the amount of infectious viruses harvested after 16, 24, and 48 h of infection in the presence of 0-100 µM MGBG was determined by plaque assays (Fig. 1C) . The number of infectious viruses produced was MGBG dose dependent. For example, there were 3×, 6×, 18×, and 63× less infectious progeny viruses recovered at 24 h postinfection from cells treated with, respectively, 10, 25, 50, and 100 µM MGBG compared with untreated control cells. In addition, the decrease was more pronounced when cells were pre-treated.
Amount of intracellular SPM in MGBG-treated cells
Since the inhibition of SAMDC impairs the synthesis of dcSAM, we evaluated the amount of intracellular SPM in cells exposed to MGBG. Cells were grown in the presence of 100 µM MGBG, and MGBG was added concomitantly with virions in infected cells. There is a 35-40% decrease of the intracellular SPM content in both mock-infected and HSV-1-infected cells exposed for 12 and 24 h to MGBG, compared with the control untreated mock-infected cells (Fig. 1D) .
Regulation of SAMDC gene expression during infection
Because the HSV-1-induced shutoff of cellular protein synthesis is mainly due to mRNA degradation and to inhibition of mRNA translation, we estimated the level of SAMDC mRNA during HSV-1 infection and analyzed its recruitment into polyribosomes during the course of infection. Total cytplasmic RNAs were purified from mock-infected cells and from cells infected for 3-12 h. Infection was performed in the same experimental conditions than those we have used in previous studies to analyze the behavior of different cellular mRNAs, i.e., those coding for β actin, GAPDH, and ribosomal proteins. This allows the comparison of the results obtained for SAMDC mRNA with those of these mRNAs (8, 9, 13). The amount of SAMDC mRNA increased progressively during infection until 9 h postinfection contrary to that of the control of β actin mRNA, which, as expected, was progressively degraded ( Fig. 2A; ref 8 ).
To investigate the efficiency of translation of SAMDC mRNA, we traced its ability to recruit ribosomes. The distribution of SAMDC mRNAs in polyribosomal fractions varied according to the time of infection (Fig. 2B, b and c) . Free SAMDC mRNAs present in the supernatant and SAMDC mRNAs associated with the 40S ribosomal subunits progressively decreased during the course of infection (fractions 1-6), whereas those present onto polyribosomes progressively increased (fractions 10-20). SAMDC mRNAs were present mainly among mono-ribosomes in mock-infected cells (fractions 8 and 9), and among polyribosomes containing two to three ribosomes per mRNA molecule (fractions 10-11), and more than three ribosomes per mRNA (fractions 12-15) in cells infected for 6 and 9 h, respectively.
Effect of MGBG on cell growth and viability
The cytotoxic effects of MGBG at concentrations required for antiviral effect were investigated on cell growth and viability. Experiments were conducted on uninfected cells submitted to MGBG treatment for 24 to 48 h. There was only a weak difference in the growth rate of cells treated for 24 and 30 h with 10-200 µM MGBG compared with control untreated cells (Fig. 3) . 
SAMDC inhibition and amount of viral products
To elucidate the mechanism responsible for the inhibition of viral infection after inhibition of SAMDC, we investigated the behavior of viral proteins, mRNA, and DNA. Cells pre-exposed or not to 10-200 µM of MGBG for 24 h were infected in the presence of the same concentrations of MGBG. We investigated ICP27, UL42, and Us11 viral proteins that are synthesized during the immediate-early, the early and the late phases of infection respectively. Results clearly show that increasing concentrations of MGBG led to a significant decrease in the level of viral proteins of the three classes and the corresponding mRNAs, as well as the viral DNA (Fig. 4A) . In cells treated with 25 µM MGBG, there was a 75% decrease in the amount of viral mRNAs and of viral DNA compared with control untreated-infected cells, and the amount of the corresponding proteins decreased simultaneously. In the presence of 50 µM of MGBG, the amount of viral DNA and RNA represented <2% of the control. In the presence of higher concentrations of MGBG, the viral products were barely detectable.
Incidence of MGBG added after virus adsorption and penetration
Entry of viruses into the host cell is a multistep process, including adsorption to cell membrane and penetration of the viral particles. The above results show that the inhibition of the viral infection depends on the concentration and on the time of exposure of the cells to MGBG, indicating that the inhibition is due, at least in part, to the decrease in the amount of the intracellular SPD or SPM. However, the inhibition could also result from the inhibition of adsorption or penetration of viral particles into the host cells. To gain insights into the mechanism of inhibition, viral infection was further examined when MGBG treatment started either at the beginning of infection, or after the adsorption step or penetration of the virus (Fig.  4B) . Infection was totally prevented when MGBG was added at the beginning of infection, or 2 h later. In addition, viral infection was still severely repressed when MGBG was added 4 or 6 h postinfection.
Outcome of infection in MGBG-treated cells in presence of exogenous SPM
To verify whether infection depends on the amount of intracellular polyamines, we tested whether the supply of exogenous SPM to infected cells treated with MGBG could prevent the inhibition of viral infection. Cells were pretreated with 100 µM MGBG, and then infected in the presence of MGBG alone or with both MGBG and SPM (Fig. 5) . As expected, viral DNA, mRNA, and proteins were barely detectable or were undetectable in infected cells exposed to MGBG alone. In these cells, the amounts of viral DNA and mRNAs represented 2-5% of that of the control untreated infected cells. On the contrary, high amounts of viral products were present in infected cells exposed to both MGBG and SPM. In this case, the amounts of viral DNA and mRNAs increased to 43-68% of the control, respectively.
Similar results were found when SPD was used instead of SPM or when SPM was added to cell medium 2 or 4 h after the beginning of infection and, therefore, after the beginning of MGBG treatment (data not shown).
Effect of SAMDC inhibition on the viral cycle
We then determined more precisely at which stage of the lytic viral cycle the MGBG-induced inhibition of infection takes place. We traced viral proteins and DNA all along infection in cells exposed or not to 100 µM MGBG and 0.5 PFU per cell (Fig. 6A) . During the immediate-early and the early phases of the first round of infection, the amount of immediate-early protein ICP27 was not significantly affected by MGBG treatment. After 20 h of infection, the amount of ICP27 was lower in MGBG-treated cells than in untreated cells. The early protein UL42 and the late protein Us11 were at a lower level in MGBG-treated cells compared with control untreated infected cells. Similarly, in experiments performed with cells infected at higher MOI (20 PFU per cell), the amounts of UL42 and Us11 were decreased in MGBG-treated cells compared with untreated cells, and not that of ICP27 (data not shown). In addition, as soon as the viral DNA was detectable, its amount was weaker in MGBG-treated cells than in untreated cells. At 12 h postinfection, the amount of viral DNA was barely detectable in untreated cells, and undetectable in MGBG-treated cells. From 16 to 24 h postinfection, the amounts of viral DNA were 5-20 times less in MGBG-treated cells compared with untreated cells. Results obtained in these experimental conditions indicate that 3, 6, and 9 h postinfection correspond to the immediateearly and early phases of the first round of infection, 12-16 h postinfection to the late phase of the first round of infection, and 20 and 24 h postinfection to the end of the first round or the beginning of the second round of infection. During the first round of infection, the amount of the immediate-early protein ICP27 was not affected, contrary to the amounts of the viral DNA and of the early UL42 and late Us11 proteins, which were strongly decreased. The amount of viral DNA was decreased also when cells were infected with a higher MOI (2 and 20 PFU instead of 0.5), and a lower concentration of MGBG (25 µM instead of 100 µM), and when MGBG was added at 4 h postinfection, after the entry step (Fig. 6B) .
Effect of SAMDC inhibition on the replication of drug-resistant HSV-1 strains
We next examined whether the inhibition of SAMDC activity prevents infection from ACV and/or foscarnet-resistant HSV-1 strains. We tested three nonsyncitial HSV-1 reference strains: the SC16 ACV and foscarnet susceptible reference strain, the DM21 ACV resistant reference strain, and the TP2.5 ACV and foscarnet resistant reference strain both derived from SC16 (31) (32) (33) . In each experiment, dose-response curves were constructed for cycloheximide, ACV, foscarnet, and MGBG, and the IC 50 values were calculated ( Table 1 ). All the strains presented the same susceptibility to MGBG, even though the virus was resistant to ACV or resistant to both ACV and foscarnet. Strains resistant to one or more antiviral drugs became somewhat more susceptible to the other antiviral drugs. ACV-resistant strain DM21 exhibited higher susceptibility to foscarnet than susceptible strain SC16 (34% decreased IC 50 ). In addition, the MGBG-induced inhibition of viral infection was more complete in cells infected with the two resistant strains DM21 and TP2.5, with a 27 and 20% decreased IC 50 , respectively, compared with the value observed for the susceptible strain SC16. In addition, MGBG inhibited replication of HSV-1 clinical ACV or foscarnet-resistant isolates (data not shown). Here we show that inhibition of polyamine metabolic pathway prevents HSV-1 infection. We note that viral infection is very efficiently prevented when SAMDC activity is inhibited by MGBG while inhibition of ODC by DFMO leads only to a slight decrease of infection. This could be due to the fact that SAMDC acts downstream of ODC in polyamine synthesis and that its product dcSAM takes part to the synthesis of both SPD and SPM. Therefore, we further focused on SAMDC. Our results indicate that the inhibition of viral infection and of the production of infectious progeny virus depends on the concentration of MGBG and on the time of pre-exposure of the cells to MGBG.
Because SAMDC activity is required for the outcome of HSV-1 infection, we asked whether SAMDC gene expression is sustained during the course of infection. In mammalian cells, SAMDC has a very short half-life and its expression is regulated both at the transcriptional and the translational levels. In HSV-1-infected cells, the virally induced shutoff of cellular protein synthesis is mainly due to mRNA degradation and to inhibition of mRNA translation. In this study, Western blot analyses have been hampered by the fact that SAMDC is present in very low amounts. Therefore, we estimated the level of SAMDC mRNA and compared its recruitment into polyribosomes during the course of infection.
Our data show that SAMDC gene expression is stimulated in HSV-1-infected cells. Indeed, SAMDC mRNA level increased in response to infection. The very few cellular mRNA that behave this way usually encode proteins the synthesis of which is maintained after infection, i.e., ubiquitin, stress proteins, ε-and β-globin, and histone H3 (13, 16, 38-41). Our results also show that upon infection SAMDC mRNAs are redistributed from polyribosomes of small size into larger polyribosomes. This indicates that SAMDC mRNAs are more efficiently translated after infection than before. Furthermore, ODC synthesis is also stimulated upon HSV-1 infection (protein number 198 in ref. 14). Therefore, the expression of both ODC and SAMDC, two key enzymes of the polyamine biosynthesis, is up-regulated in infected cells, indicating that this metabolic pathway is still functional. We have already shown that this is the case for ribosome biogenesis (8, 13). This seems to be the case also for cyclin (42) .
The maintenance of an active polyamine biosynthetic pathway argues for a role of polyamines during HSV-1 replicative cycle. Here we report a strong decrease in the global intracellular SPM content in MGBG-treated cells. Only a small fraction of intracellular polyamines is free and metabolically active, the remainder associates tightly with cellular components. Therefore, the MGBG-induced decrease of the SPM level likely corresponds to an almost complete decrease in the amount of free SPM. Our present data demonstrate that SAMDC activity is required for HSV-1 replication in human cells, likely by maintaining a sufficient amount of intracellular polyamines.
Polyamines are involved in a variety of cellular processes and functions, i.e., cell division, growth, differentiation, apoptosis, replication, transcription, protein synthesis, and posttranslational modifications (43, 44) . In addition, MGBG and polyamines share the same pathway for intracellular uptake and compete for binding to negatively charged sites (45, 46) . We conducted experiments to investigate the mechanism of the MGBG-induced inhibition of infection. We show that inhibition of infection is more efficient in cells pre-exposed to MGBG. However, inhibition occurs wherever MGBG is added before or after the virus entry step. Moreover, exogenous SPM prevents the MGBG-induced inhibition of infection even when added after penetration. This means that inhibition of infection is due rather to the decreased amount of available polyamines than to inhibition of viral adsorption or entry into cells or to competition among MGBG, polyamines, and viral particles to enter into the cells. Indeed, the inhibition of infection takes place during the first round of infection, after the beginning of the synthesis of immediate-early proteins, and before or during the replication of viral DNA, since the amounts of early and late proteins are lower in the presence of MGBG than in the absence, whereas that of immediate early protein is not significantly affected, and since the amount of viral DNA is decreased with the same efficiency whatever MGBG is added at the time of infection or several hours after the penetration step. Therefore, polyamines play a pivotal role in the replication of viral DNA and likely in late events of infection. This notion is supported by the facts that 1) polyamines are shown to be involved in the replication of HSV-1 DNA in a cell-free system and of cellular DNA, 2) activation of polyamine pathway is correlated with the synthesis of DNA and RNA, and 3) polyamines are components of HSV particles (17, 47-49).
MGBG inhibits in vitro the replication of HSV-1 laboratory mutants strains and of clinical mutant isolates that are resistant to conventional antiviral drugs, e.g., ACV and foscarnet. These drugs are nucleotide analogs that inhibit the viral thymidine kinase and/or DNA polymerase. As with other viruses, drug-resistant variants often emerge from treated patients in response to drug therapy. The appearance of viral mutants has become a major problem. Indeed, some of the immunocompromised patients are not able to control infection. Thus, frequent and severe reactivations are seen and led to HSV infections that are often resistant to antiviral drug therapy. All available anti-herpetic drugs and new drugs announced to be in development act on viral enzymes and thus increase the risk of emergence of more resistant viral strains. Accordingly, the development of an antiviral strategy targeting a cellular component necessary for the viral replication, rather than a viral component, makes it possible to avoid the emergence of drugresistant viruses. In addition, the inhibition of infection is more complete when MGBG and ACV are used in combination rather than alone (data not shown), indicating that the two drugs act on distinct mechanisms. One can expect that, in the future, the alternative use of these latter drugs together with conventional drugs for the management of herpetic infections could reduce the appearance and dissemination of drug-resistant viruses. 3-8) . Cells were then infected with 0.5 PFU per cell. Lanes 1 and 2 correspond to controls of untreated mock-infected and infected cells, respectively. Cells were harvested at 24 h p.i., and total proteins, RNA, and DNA were extracted. Immediate-early, early, and late viral proteins were analyzed by Western blots using anti-ICP27, UL42, and Us11 antibodies, respectively. Amounts of viral mRNA and DNA were estimated by slot blot analysis using specific viral probes; PhosphorImager images of the membranes are presented. B) Effect of MGBG added after entry. Cells were infected with 0.5 PFU per cell in SVF-free medium; 100 µM of MGBG was added to cell medium either with viral suspension (0 h) or 2 to 6 h later until end of experiment as indicated in each panel. Light microscope pictures were taken at 48 h p.i. (×400 magnification). 
